ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm sets progression-free survival as primary endpoint for 1,100-patient trial.
You may also be interested in...
ImClone’s Late-stage Pipeline Includes A Potential Erbitux Competitor
Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.
ImClone’s Late-stage Pipeline Includes A Potential Erbitux Competitor
Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.
North American Erbitux Sales Up 17 Percent In First Quarter
Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.